Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2, cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin e synthase-1

Chemical Biology and Drug Design

Volumn 83, Issue 6, 2014, Pages 670-681

  Ahmad, Waqas ^a   Kumolosasi, Endang ^a   Jantan, Ibrahim ^a   Bukhari, Syed N A ^a   Jasamai, Malina ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

chemical biology; drug discovery; enzymatic mechanism

Indexed keywords

1 5 BIS[2,3(DIMETHOXY)PHENYL] 1,4 PENTADIEN 3 ONE; 1,5 BIS[2 METHYL 4(N ETHYL N ETHYLACETONITRILE)ANILINE] 1,4 PENTADIENE 3 ONE; 1,5 BIS[4 (METHYLAMINOETHANOL)PHENYL] 1,4 PENTADIENE 3 ONE; 2,5 BIS(4 DIETHYLAMINOBENZYLIDENE)CYCLOPENTANONE; 2,5 BIS[4 (METHYLAMINOETHANOL)BENZYLIDENE]CYCLOPENTANONE; 2,6 BIS(2,3 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(4 DIETHYL AMINOBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS[2 METHYL 4(N ETHYL N ETHYLACETONITRILE)ANILINE]CYCLOHEXANONE; 2,6 BIS[4 (METHYLAMINOETHANOL)BENZYLIDINE]CYCLOHEXANONE; CURCUMIN; DEXAMETHASONE; DIARYLPENTANOID ANALOGUE; LIPOXYGENASE; PHOSPHOLIPASE A2; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ISOMERASE; PROSTAGLANDIN E SYNTHASE; SECRETORY PHOSPHOLIPASE A2;

ARTICLE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; IC50; METABOLISM; MICROSOME;

CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; INTRAMOLECULAR OXIDOREDUCTASES; LIPOXYGENASE; MICROSOMES; PHOSPHOLIPASES A2, SECRETORY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 84901046535     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12280     Document Type: Article

References (36)

1. Cuendet M., Pezzuto J.M., (2000) The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metab Drug Interact; 17: 109-157.
2. 2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis; 25: 1671-1679.
3. Aggarwal B.B., Surh Y.J., Shishodia S., (2007) The molecular targets and therapeutic uses of curcumin in health and disease, advances in experimental medicine and biology. New York: Springer.
4. Lal J., Gupta S.K., Thavaselvam D., Agarwal D.D., (2012) Design, synthesis, synergistic antimicrobial activity and cytotoxicity of 4-aryl substituted 3,4 dihydropyrimidinones of curcumin. Bioorg Med Chem Lett; 22: 2872-2876.
5. Magerramov A.M., Kurbanona M.M., Abdinbekova R.T., Rzaeva I.A., Farzaliev V.M., Allakhverdiev M.A., (2006) Synthesis and antioxidative properties of some 3,4-dihydropyrimidin-2(1H)ones (-thiones). Russ J Appl Chem; 79: 787-790.
6. Feng R., Lu Y., Bowman L.L., Qian Y., Castranova V., Ding M., (2005) Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem; 280: 27888-27895.
7. Shakibaei M., (2007) Suppression of NF-kB activation by curcumin leads to inhibition of expression of cyclooxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes; Implications for the treatment of osteoarthritis. Biochem Pharmacol; 73: 1434-1445.
8. Kohli K., Ali J., Ansari M., Raheman Z., (2005) Curcumin; a natural anti-inflammatory agent. Indian J Pharmacol; 37: 141-147.
9. Chun K.S., Keum Y.S., Han S.S., Song Y.S., Kim S.H., Surh Y.J., (2003) Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal regulated kinase activity and NF-kB activation. Carcinogenesis; 24: 1515-1524.
10. Huang M.T., Lysz T., Ferraro T., Abidi T.F., Laskin J.D., Conney A.H., (1991) Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res; 51: 813-819.
11. Anand P., Kunnumakkara A., Newman R., Aggarwal B., (2007) Bioavailability of curcumin: problems and promises. Mol Pharm; 4: 807-818.
12. Straganz G.D., Nidetzky J., (2005) Reaction coordinate analysis for β-diketone cleavage by the non-heme Fe2+ dependent dioxygenase dke1. J Am Chem Soc; 127: 12306-12314.
13. Liang G., Yang S., Zhou H., Shao L., Huang K., Xiao J., Huang Z., Li X., (2009) Synthesis, crystal structure and anti-inflammatory properties of curcumin analogues. Eur J Med Chem; 44: 915-919.
14. Jantan I., Bukhari S., Lajis N., Abas F., Wai L., Jasmai M., (2012) Effects of diarylpentanoid analogues of curcumin on chemiluminescence and chemotactic activities of phagocytes. J Pharm Pharmacol; 64: 404-412.
15. Ellman G.L., Courtney K.D., Andres V., Feather-stone R.M., (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol; 7: 88-95.
16. Weinstein D.S., Liu W., Gu Z., Langevine C., Ngu K., Fadnis L., Combs D.W., et al,. (2005) Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase. Bioorg Med Chem; 15: 1435-1440.
17. Blobaum A.L., Marnett L.J., (2007) Structural and functional basis of cyclooxygenase inhibition. J Med Chem; 50: 1425-1441.
18. Masse F., Guiral S., Fortin L.J., Cauchon E., Ethier D., Guay J., Brideau C., (2005) An automated multistep high-throughput screening assay for the identification of lead inhibitors of the inducible enzyme mPGES-1. J Biomol Screen; 10: 599-605.
19. Dennis E.A., (2000) Phospholipase A2 in eicosanoid generation. Am J Respir Crit Care Med; 161: S32-S35.
20. 2 as a therapeutic target. Biochim Biophys Acta; 1488: 182-187.
21. 2 isoforms: a perspective. Cell Signal; 15: 637-665.
22. Kim H.P., Son K.H., Chang H.W., Kang S.S., (2004) Anti-inflammatory plant flavonoids and cellular action mechanism. J Pharmacol Sci; 96: 229-245.
23. Fournier D.B., Gordon G.B., (2000) COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl; 34: 97-102.
24. Jachak S.M., (2006) Cyclooxygenase inhibitory natural products: current status. Curr Med Chem; 13: 659-678.
25. Herrera-Salgado Y., Garduno-Ramírez M.L., Vazquez L., Rios M.Y., Alvarez L., (2005) Myo-inositol-derived glycolipids with anti-inflammatory activity from Solanum lanceolatum. J Nat Prod; 68: 1031-1036.
26. Jovanovic D.V., Fernandes J.C., Martel-Pelletier J., Jolicoeur F.C., Reboul P., Laufer S., Tries S., Pelletier J.P., (2001) In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. Arthritis Rheum; 10: 2320-2330.
27. Brash A.R., (1999) Lipoxygenases: occurrence, functions, catalysis and acquisition of Substrate. J Biol Chem; 274: 23679-23682.
28. Katsori A.M., Chatzopoulou M., Dimas K., Kontogiorgis C., Patsilinakos A., Trangas T., Hadjipavlou-Litina D., (2011) Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. Eur J Med Chem; 46: 2722-2735.
29. Rao C.V., (2007) Regulation of COX and LOX by curcumin. Adv Exp Med Biol; 595: 213-226.
30. Samuelsson B., Morgenstern R., Jakobsson P.J., (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev; 59: 207-224.
31. Thoren S., Jakobsson P.J., (2000) Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur J Biochem; 267: 6428-6434.
32. Friesen R.W., Mancini J.A., (2008) Microsomal prostaglandin E2 synthase-1(mPGES-1): a novel anti-inflammatory therapeutic target. J Med Chem; 51: 4059-4067.
33. Plummer S.M., Hill K.A., Festing M.F., (2001) Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev; 10: 1295-1299.
34. Sharma R.A., Gescher A.J., Steward W.P., (2005) Curcumin: the story so far. Eur J Cancer; 41: 1955-1968.
35. Moon Y., Glasgow W.C., Eling T.E., (2005) Curcumin suppresses interleukin 1β- mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. J Pharm Exp Ther; 315: 788-795.
36. 2 synthase-1. Mol Cancer Ther; 8: 2348-2355.